Genesis Unicorn Capital Corp. announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GENQU” Tuesday, February 15.
The new SPAC intends to focus its search on the intersection of the healthcare and technology industries, specifically within the biotechnology and pharmaceutical sectors. Genesis Unicorn Capital is led by Chief Executive Officer Adeoye Olukotun, President and Chief Financial Officer Samuel Liu, Chief Scientific Officer Niel Starksen, Chief Operating Officer Juan Fernandez Pascual, and Co-Chairmen Grainne Coen and Ernest Fong.
Total SPAC deal count for 2022 year-to-date is now 37. This offering is expected to close on Thursday, February 17.
EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book running manager for the offering. Becker & Poliakoff LLP is serving as Issuer’s Counsel with Hogan Lovells US LLP serving as Underwriter’s Counsel. MaloneBailey, LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Yorkville Acquisition Corp. (NASDAQ:YORKU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “YORKU”, Friday, June 27, 2025. The new SPAC plans to combine with a target company in the telecom, media or technology sectors. Yorkville Acquisition Corp.’s management team is led...
At the SPAC of Dawn As pressure on Fed Chairman Jerome Powell increases, the market is set to ingest a raft of new indicators today as well as hear from Cleveland Fed President Beth Hammack on the potential interest rate path. Today will also see June’s 8th SPAC IPO as Cantor Equity Partners III Inc....
Cantor Equity Partners III Inc. (NASDAQ:CAEP) announced the pricing of its upsized $240 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “CAEP”, Thursday, June 26, 2025. The new SPAC plans to combine with a target company in an industry where its management has relevant expertise such financial...
Launch One (NASDAQ:LPAA) has entered into a definitive agreement to combine with biotech firm Minovia Therapeutics at a $180 million pre-money valuation. Haifa, Israel-based Minovia is developing a drug platform based on mitochondrial cell therapies to potentially treat rare disorders as well as the effects of aging and other causes of bodily degeneration. The combined...
CEO Marc Nemati and Colombier II’s Omeed Malik break down the deal and the strategy. Despite its moniker as the “the everything store” you can’t buy everything on Amazon, and firearms are one of those things. But, GrabAGun has spent years building a platform for regulated online firearms purchases, and soon, consumers will be able...